Table 5.
Metabolites and their ratios | Saline (N = 23) | Acute AMPH (N = 30) | Repeated AMPH (N = 26) | Kruskal–Wallis test | Effect size (η2) |
---|---|---|---|---|---|
C14 | 0.088 0.06–0.12 |
0.075 0.054–0.14 |
0.094b 0.059–0.18 |
= 6.19, p = 0.045 | 0.07 |
Hexoses | 7,609 4,405–11,103 |
6,053a 3,269–9,751 |
5,778c 2,764–9,625 |
= 7.31, p = 0.03 | 0.09 |
Citrulline | 51.4 28.9–112 |
45.2a 14.2–112 |
41.5c 27.5–82.0 |
= 8.51, p = 0.01 | 0.10 |
Isoleucine | 91.5 60.6–129 |
95.0 75.6–214 |
109c 62.5–208 |
= 8.66, p = 0.013 | 0.10 |
Leucine | 129 92.8–197 |
154a 107–372 |
168c 104–413 |
= 11.75, p = 0.003 | 0.13 |
ADMA | 0.34 0.11–0.75 |
0.34 0.00–1.27 |
0.26c 0.00–0.60 |
= 6.70, p = 0.04 | 0.08 |
Kynurenine | 1.42 0.93–1.90 |
1.22a 0.89–1.6 |
1.15c 0.83–1.90 |
= 12.82, p = 0.002 | 0.15 |
lysoPC a C16:0 | 302 158–444 |
225a 127–411 |
268 121–443 |
= 8.42, p = 0.02 | 0.10 |
lysoPC a C18:2 | 151 88.0–198 |
113a 61.1–242 |
114c 56.3–226 |
= 10.42, p = 0.006 | 0.12 |
PC ae C40:6 | 1.48 0.82–2.11 |
1.21 0.58–1.80 |
1.47b 0.80 - 2.53 |
= 6.82, p = 0.03 | 0.08 |
PC ae C42:1 | 0.47 0.22–0.68 |
0.42 0.17–0.66 |
0.51b 0.32–0.80 |
= 7.01, p = 0.03 | 0.08 |
BCAA | 397 308–611 |
420 305–811 |
461c 291–939 |
= 6.03, p = 0.049 | 0.07 |
*CPT1 ratio | 0.009 0.005–0.020 |
0.009 0.005–0.020 |
0.011b 0.004–0.030 |
= 8.92, p = 0.01 | 0.10 |
lysoPC a C20:4/lysoPC a C20:3 | 3.35 2.85–4.47 |
3.43 2.66–5.89 |
3.82b,c 2.91–5.71 |
= 8.59, p = 0.01 | 0.10 |
Effect size estimates for chi-square values are indicated by η2, where value ≥ 0.14 corresponds to a large effect. *CPT1 (carnitine palmitoyltransferase 1) ratio [(C16 + C18)/carnitine].
Statistically significant difference (p < 0.05) between saline and acute AMPH.
Statistically significant difference (p < 0.05) between acute AMPH and repeated AMPH.
Statistically significant difference (p < 0.05) between saline and repeated AMPH.